OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 11:35:17 2024-07-02 EDT | ||
| 1.8 EUR | +2.27% |
|
| Current month | -0.56% | ||
| 1 month | +10.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 1.8 | +2.27% |
| 24-07-01 | 1.76 | -0.56% |
| 24-06-28 | 1.77 | -1.67% |
| 24-06-27 | 1.8 | +0.56% |
| 24-06-26 | 1.79 | +1.13% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 11:35 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | HG33Z1 |
| ISIN | DE000HG33Z15 |
| Date issued | 2022-05-16 |
| Strike | 284.5 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.89 € |
|---|---|
| Lowest since issue | 0.06 € |
| Spread | 0.01 € |
| Spread % | 0.56% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
471.2
USD
Average target price
468.3
USD
Spread / Average Target
-0.63%
- Stock Market
- Certificates
- Certificat
